Dangerous heart drug

Hannon, Kerry; Mannix, Margaret
August 1993
U.S. News & World Report;8/2/93, Vol. 115 Issue 5, p57
Warns that patients who take the heart-failure drug flosequinan, better known as Manoplax, should contact their doctor immediately. Increases the risk of hospitalization for congestive heart failure and of death; Urgent appeal comes from the drug's maker, Boots Pharmaceuticals, which voluntarily pulled the drug from the market; Hot line for more information; Details.


Related Articles

  • Amgen recalls anemia drugs due to glass flakes.  // Tennessee Tribune;9/30/2010, Vol. 21 Issue 39, p5B 

    The article reports on the recall of anemia treatment drugs Epogen and Procrit by Amgen Inc. due to its tendency to cause blood clots, veins swelling and immune system reactions in the U.S.

  • WHAT'S NEW IN DRUGS.  // RN;Mar80, Vol. 43 Issue 3, p93 

    Presents news briefs on two drugs available as of March 1980. Indications of Nadolol; Details on the recall of Ticrynafen from the market.

  • Canada recalls Chinese mercury, lead drug.  // South Asian Post;9/27/2012, p21 

    The article reports on the recall of the unauthorized natural health drug Zhuifeng Tougu Wan imported from China and distributed in Vancouver, British Columbia and Toronto, Ontario which Health Canada claims to have high mercury, lead and arsenic levels.

  • GSK recalls Children's Panadol Baby Drops Syringes.  // Australian Journal of Pharmacy;Jan2014, Vol. 95 Issue 1124, p24 

    The article informs that the Children's Panadol Baby Drops Syringe has been recalled by the pharmaceutical company GlaxoSmithKline and discusses the objectives of the company with the patient safety, quality and continued supply of medicines to customers.

  • Bayer Pulls Baycol in Japan; Roche Denies Drugs Bid.  // Chemical Week;8/29/2001, Vol. 163 Issue 32/33, p6 

    Reports the recall of the Baycol/Lipobay cholesterol-lowering drug by Bayer in Japan. Collapse of the company's share price; Impact of the withdrawal on the operating profits of the company; Denial of Roche to reports on its interest to acquire the company.

  • Product Recalls.  // Health Letter;Aug2014, p5 

    The article lists recalled medicines, which include 7-tablet sample bottles of 20 mg Bystolic (nebivolol), 100-count bottles of 10 mg Dextroamphetamine sulfate tablets, and 30-, 100-, and 1000-count bottles of 300 mg Isoniazid tablets.

  • Product Recalls.  // Health Letter;Jun2015, p1 

    The article lists the products that have been recalled from April 16 till May 13, 2015, including Captopril tablets, 12.5 mg; Fluoxetine capsules, 10 mg; and Minivelle (estradiol transdermal system) 0.05 mg/day.

  • Product Recalls.  // Health Letter;Aug2015, p1 

    The article lists the drugs which were recalled during the period June 11 - July 8. 2015, which include 100-count and 500-count bottles of Divalproex sodium extended-release tablets, 250 mg, 100-count bottles of 500 mg, and Lamivudine and Zidovudine tablets,

  • Product Recalls.  // Health Letter;Jan2015, p1 

    The article lists CLASS II medicinal tablets that have been recalled including Diclofenac sodium, Losartan and Mercaptopurine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics